Pluristem Therapeutics - PSTI Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PSTI shares.
View PSTI analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year target prices for Pluristem Therapeutics' stock. Their PSTI share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for PSTI or view top-rated stocks among Wall Street analysts.

Pluristem Therapeutics' stock was trading at $1.46 at the beginning of 2022. Since then, PSTI stock has decreased by 31.5% and is now trading at $1.00.
View the best growth stocks for 2022 here.

Pluristem Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, September 12th 2022.
View our PSTI earnings forecast.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) issued its earnings results on Monday, November, 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.05.

Pluristem Therapeutics shares reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Protalix BioTherapeutics (PLX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

Pluristem Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Green Alpha Advisors LLC (2.51%). Insiders that own company stock include Clover Wolf Capital - Limited and Zami Aberman.
View institutional ownership trends.

Shares of PSTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PSTI stock can currently be purchased for approximately $1.00.

Pluristem Therapeutics (NASDAQ:PSTI) has a market capitalization of $32.35 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-49,870,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

Pluristem Therapeutics employs 153 workers across the globe.

Pluristem Therapeutics was founded in 2003.

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The official website for the company is www.pluristem.com. The biotechnology company can be reached via phone at 972747107171, via email at danar@pluristem.com, or via fax at 972-74-710-8787.